AmgenvsCorcept Therapeutics

AMGN and CORT stock compared: price, dividend, valuation and results, from SEC filings.

AMGN

Amgen Inc.

$462.32

Value $249B

-0.30%
AMGN's page

CORT

Corcept Therapeutics Incorporated

$69.22

Value $7.4B

-1.04%
CORT's page

Amgen (AMGN) has a market value of $249B and Corcept Therapeutics (CORT) $7.4B. Over the last year, with dividends, AMGN moved +42.3% and CORT -7.0%. The P/E is 26.5 for AMGN and 46.2 for CORT. Dividend yield: AMGN 2.15%, CORT none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AMGN$249B

    CORT$7.4B

    AMGN is 34 times CORT

  • Revenue, 12 months

    AMGN$38.9B

    CORT$964M

    AMGN is 40 times CORT

  • Net income, 12 months

    AMGN$9.4B

    CORT$162M

    AMGN is 58 times CORT

  • Operating margin

    AMGN32.4%

    CORT11.5%

    20.9 points apart

  • ROIC

    AMGN16.2%

    CORT12.7%

    3.5 points apart

  • P/E

    AMGN26.5

    CORT46.2

    CORT is 1.7 times AMGN

  • Dividend yield

    AMGN2.2%

    CORT0.0%

    2.2 points apart

  • 5-year return

    AMGN+157.4%

    CORT+217.1%

    59.7 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AMGN+157.4%

CORT+217.1%

20040020222023202420252026
Returns by period
PeriodAMGNWith dividendsCORTWith dividends
1 year since November 12, 2025+42.3%Price +38.5%-7.0%Price -7.0%
3 years since November 13, 2023+91.0%+24.1% a yearPrice +74.6%+193.9%+43.2% a yearPrice +193.9%
5 years since November 12, 2021+157.4%+20.8% a yearPrice +120.3%+217.1%+26.0% a yearPrice +217.1%
10 years since November 16, 2016+323.1%+15.5% a yearPrice +216.3%+671.0%+22.7% a yearPrice +671.0%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AMGNAmgenCORTCorcept Therapeutics

Valuation

AMGNCORT
Valuation
Price$462.32$69.22
Market value$249B$7.4B
Enterprise value (EV)$290B$7.0B
P/E26.546.2
P/E, 5-year median23.034.6
P/B17.48.8
EV/EBIT23.063.1
Free cash flow yield3.8%2.6%

Results and growth

AMGNCORT
Results and growth
Revenue, 12 months$38.9B$964M
Net income, 12 months$9.4B$162M
Free cash flow, 12 months$9.6B$195M
Earnings per share, 12 months$17.25$1.50
Revenue growth, year on year10.0%12.8%
Revenue growth a year, past+7.6%over 5 years+16.6%over 5 years
EPS growth a year, past+2.9%over 5 years-0.7%over 5 years

Margins and returns on capital

AMGNCORT
Margins and returns on capital
Gross margin70.9%98.5%
Operating margin32.4%11.5%
Net margin24.1%16.8%
ROIC16.2%12.7%
ROE87.8%23.5%

Balance sheet

AMGNCORT
Balance sheet
Cash$13.2B$371M
Total debt$54.0B$9.0M
Net debt / EBITDA2.3-3.3
Interest cover4.8×–

Dividends and buybacks

AMGNCORT
Dividends and buybacks
Dividend yield2.2%–
Dividend per share, 12 months$9.94–
Dividend growth a year, past+8.1%over 5 years–
Buyback yield–2.4%
Shareholder yield2.2%2.4%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AMGN or CORT

Didn't find what you were looking for?

Ask us
Which is bigger, Amgen or Corcept Therapeutics?

By market value, Amgen ($249B) is about 33.8 times Corcept Therapeutics ($7.4B), at today's prices.

How did AMGN and CORT stock do over the last 10 years?

Since November 16, 2016, AMGN's price moved +216.3% and CORT's +671.0%. With dividends: AMGN +323.1% (+15.5% a year), CORT +671.0% (+22.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, AMGN or CORT?

The dividend yield at today's price is 2.15% for Amgen and none for Corcept Therapeutics. Over the last twelve months they paid $9.94 and – per share.

What is the P/E of AMGN and CORT?

At today's price, the P/E is 26.5 for AMGN and 46.2 for CORT. The median of the last five years was 23.0 and 34.6, which shows where each stands against its own past.

Which has the higher profit margins, Amgen or Corcept Therapeutics?

Over the last twelve months, the net margin was 24.1% for Amgen and 16.8% for Corcept Therapeutics, and the operating margin 32.4% and 11.5%. Revenue was $38.9B and $964M.

Which is the better investment, Amgen or Corcept Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.